Moteur de recherche d’entreprises européennes

Financement britannique (718 774 £) : CP-STAR - Catylystes captifs : fabrication de haute pureté de produits pharmaceutiques de haute qualité et de biotechnologie de grande valeur Ukri 01/10/2009 Recherche et innovation du Royaume-Uni, Royaume Uni

Vue d’ensemble

Texte

CP-STAR - Catylystes captifs : fabrication de haute pureté de produits pharmaceutiques de haute qualité et de biotechnologie de grande valeur

Abstract This industry-led project will enable new approaches to process chemistry based on advances in synthetic methods. The project investigates 'tethering' of new catalyst ligands to solid supports (such as polymer beads or porous surfaces) to prevent catalyst and reagent residues ending up in products and allow re-use and recycling. This also enables new, intensive flow manufacturing processes to be investigated. Over 3 years the project aims to take the background science through to the point of real application trials in high value manufacturing processes. The expected benefits to the chemicals, pharmaceutical and biotech sectors are: 1) compliance with regulatory metal contamination limits in drug manufacture without expensive purification processes and reducing need for plant cleaning; 2) enabling use of novel catalysts, including chemistry to avoid alkylating reagents in pharma synthesis; 3) enabling re-use of catalysts, reducing catalyst and solvent consumption, reducing use of limited specialist metal resources; 4) designing 'scaleability' and ‘recyclability’ into new catalyst systems for application in commercial processes, supporting resource and process intensification.
Category Collaborative R&D
Reference 100734
Status Closed
Funded period start 01/10/2009
Funded period end 31/05/2013
Funded value £718 774,00
Source https://gtr.ukri.org/projects?ref=100734

Participating Organisations

YPROTECH LIMITED

£188 666,00

PFIZER LIMITED
UNIVERSITY OF CAMBRIDGE

£247 358,00

ASTRAZENECA PLC
UNIVERSITY OF LEEDS

£282 750,00

Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Apex Molecular Ltd., Manchester, Royaume Uni.